Advanced search
Publication Cover
Expert Opinion on Medical Diagnostics Volume 1, 2007 - Issue 1
Journal homepage
45
Views
1
CrossRef citations to date
0
Altmetric
Review

Molecular diagnostics of non-Hodgkin lymphoma

Jason D Merker Molecular Genetic Pathology Fellow, Stanford University Medical Center, 300 Pasteur Drive, L235, Stanford, California 94305-5324, USA
, MD PhD &
Daniel A Arber Professor and Associate Chair of Pathology Stanford University Medical Center, 300 Pasteur Drive, H1507 Stanford, California 94305 5627, USA +1 650 725 5604;+1 650 736 1473;[email protected]
, MD
Pages 47-63 | Published online: 12 Sep 2007

Bibliography

  • JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2001).
  • ARBER DA: Molecular diagnostics in neoplastic hematopathology. In: Cancer Diagnostics: Current and Future Trends. Nakamura RM, Grody WW, Wu JT, Nagle RB (Eds), Humana Press, Inc., Totawa, NJ, USA (2004):233-259.
  • MARIAPPAN MR, ARBER DA: Molecular diagnostics in hematopathology. In: Molecular Genetic Testing in Surgical Pathology. Pfeifer JD (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA (2006):250-274.
  • KORSMEYER SJ, HIETER PA, REVETCH JV, POPLACK DG, WALDMANN TA, LEDER P: Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc. Natl. Acad. Sci. USA (1981) 78:7096-7100.
  • COSSMAN J, UPPENKAMP M, SUNDEEN J, COUPLAND R, RAFFELD M: Molecular genetics and the diagnosis of lymphoma. Arch. Pathol. Lab. Med. (1988) 112:117-127.
  • PASCUAL V, CAPRA JD: Human immunoglobulin heavy-chain variable region genes: organization, polymorphism, and expression. Adv. Immunol. (1991) 49:1-74.
  • SEGAL GH, JORGENSEN T, MASIH AS, BRAYLAN RC: Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type. Hum. Pathol. (1994) 25:1269-1275.
  • VAN DONGEN JJ, LANGERAK AW, BRUGGEMANN M et al.: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia (2003) 17:2257-2317.
  • ABDEL-REHEIM FA, EDWARDS E, ARBER DA: Utility of a rapid polymerase chain reaction panel for the detection of molecular changes in B-cell lymphoma. Arch. Pathol. Lab. Med. (1996) 120:357-363.
  • BAGG A, BRAZIEL RM, ARBER DA, BIJWAARD KE, CHU AY: Immunoglobulin heavy chain gene analysis in lymphomas: a multicenter study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J. Mol. Diagn. (2002) 4:81-89.
  • SANDBERG Y, VAN GASTEL-MOL EJ, VERHAAF B, LAM KH, VAN DONGEN JJ, LANGERAK AW: BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J. Mol. Diagn. (2005) 7:495-503.
  • VAN KRIEKEN JH, LANGERAK AW, MACINTYRE EA et al.: Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 concerted action BHM4-CT98-3936. Leukemia (2007) 21:201-206.
  • VAN BELZEN N, HUPKES PE, DOEKHARAN D, HOOGEVEEN-WESTERVELD M, DORSSERS LC, VAN'T VEER MB: Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma. Leukemia (1997) 11:1742-1752.
  • KUROKAWA T, KINOSHITA T, MURATE T et al.: Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br. J. Haematol. (1997) 98:408-412.
  • GONG JZ, ZHENG S, CHIARLE R et al.: Detection of immunoglobulin κ light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am. J. Pathol. (1999) 155:355-363.
  • PAI RK, CHAKERIAN AE, BINDER JM, AMIN M, VISWANATHA DS: B-cell clonality determination using an immunoglobulin κ light chain polymerase chain reaction method. J. Mol. Diagn. (2005) 7:300-307.
  • VAN DONGEN JJM, WOLVERS-TETTERO ILM: Analysis of immunoglobulin and T cell receptor genes. Part II. Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin. Chim. Acta (1991) 198:93-174.
  • YE BH, LISTA F, LO COCO F et al.: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 262:747-750.
  • MURAMATSU M, AKASAKA T, KADOWAKI N et al.: Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement. Br. J. Haematol. (1996) 93:911-920.
  • KAWAMATA N, NAKAMURA Y, MIKI T et al.: Detection of chimaeric transcripts of the immunoglobulin heavy chain and BCL6 genes by reverse-transcriptase polymerase chain reaction in B-cell non-Hodgkin's lymphomas. Br. J. Haematol. (1998) 100:484-489.
  • MURAMATSU M, AKASAKA T, KADOWAKI N et al.: Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leukemia (1997) 3:318-320.
  • UEDA C, AKASAKA T, OHNO H: Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications. Leuk. Lymphoma (2002) 43:1375-1381.
  • YUNIS JJ, MAYER MG, ARNESEN MA, AEPPLI DP, OKEN MM, FRIZZERA G: Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med. (1989) 320:1047-1054.
  • BASTARD C, DEWEINDT C, KERCKAERT JP et al.: LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 83:2423-2427.
  • LOSSOS IS, JONES CD, WARNKE R et al.: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 98:945-951.
  • HILL ME, MACLENNAN KA, CUNNINGHAM DC et al.: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British national lymphoma investigation study. Blood (1996) 88:1046-1051.
  • GASCOYNE RD, ADOMAT SA, KRAJEWSKI SW et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 90:244-251.
  • ALIZADEH AA, EISEN MB, DAVIS RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403:503-511.
  • ROSENWALD A, WRIGHT G, CHAN WC et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346:1937-1947.
  • SAVAGE KJ, MONTI S, KUTOK JL et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood (2003) 102:3871-3879.
  • ROSENWALD A, WRIGHT G, LEROY K et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. (2003) 198:851-862.
  • WEISS LM, WARNKE RA, SCKLAR J, CLEARY ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med. (1987) 317:1185-1189.
  • BUCHONNET G, JARDIN F, JEAN N et al.: Distribution of BCL 2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? Leukemia (2002) 16:1852-1856.
  • WEINBERG OK, AI WZ, MARIAPPAN MR, SHUM C, LEVY R, ARBER DA: “Minor” BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J. Mol. Diagn. (In Press).
  • RAMBALDI A, LAZZARI M, MANZONI C et al.: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood (2002) 99:856-862.
  • GALOIN S, AL SAATI T, SCHLAIFER D, HUYNH A, ATTAL M, DELSOL G: Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. Br. J. Haematol. (1996) 94:676-684.
  • LIMPENS J, DE JONG D, VAN KRIEKEN JH et al.: Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene (1991) 6:2271-2276.
  • OHSHIMA K, MASAHIRO K, KOBARI S, MASUDA Y, EGUCHI F, KIMURA N: Amplified bcl-2/JH rearrangements in reactive lymphadenopathy. Virchows Arch. (1993) 63:197-198.
  • LIMPENS J, STAD R, VOS C et al.: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood (1995) 85:2528-2536.
  • SUMMERS KE, GOFF LK, WILSON AG, GUPTA RK, LISTER TA, FITZGIBBON J: Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J. Clin. Oncol. (2001) 19:420-424.
  • DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351:2159-2169.
  • STEWART AK, FONSECA R: Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J. Clin. Oncol. (2005) 23:6339-6344.
  • FONSECA R, BLOOD E, RUE M et al.: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 101:4569-4575.
  • DEPIL S, LELEU X, MICOL JB et al.: Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk. Lymphoma (2004) 45:2481-2484.
  • TERPOS E, ELEUTHERAKIS-PAPAIAKOVOU V, DIMOPOULOS MA: Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk. Lymphoma (2006) 47:803-814.
  • INTINI D, BALDINI L, FABRIS S et al.: Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol. (2001) 114:362-364.
  • KEATS JJ, MAXWELL CA, TAYLOR BJ et al.: Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 105:4060-4069.
  • CHANG H, STEWART AK, QI XY, LI ZH, YI QL, TRUDEL S: Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood (2005) 106:353-355.
  • BERGSAGEL PL, KUEHL WM, ZHAN F, SAWYER J, BARLOGIE B, SHAUGHNESSY J Jr: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 106:296-303.
  • CHESI M, BERGSAGEL PL, SHONUKAN OO et al.: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 91:4457-4463.
  • FONSECA R, BARLOGIE B, BATAILLE R et al.: Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. (2004) 64:1546-1558.
  • STREUBEL B, SIMONITSCH-KLUPP I, MULLAUER L et al.: Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia (2004) 18:1722-1726.
  • ROSENWALD A, OTT G, STILGENBAUER S et al.: Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas. Am. J. Pathol. (1999) 155:1817-1821.
  • MOTEGI M, YONEZUMI M, SUZUKI H et al.: API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am. J. Pathol. (2000) 156:807-812.
  • REMSTEIN ED, JAMES CD, KURTIN PJ: Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am. J. Pathol. (2000) 156:1183-1188.
  • BAENS M, MAES B, STEYLS A, GEBOES K, MARYNEN P, DE WOLF-PEETERS C: The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am. J. Pathol. (2000) 156:1433-1439.
  • LIU H, RUSKON-FOURMESTRAUX A, LAVERGNE-SLOVE A: Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet (2001) 357:39-40.
  • STREUBEL B, VINATZER U, LAMPRECHT A, RADERER M, CHOTT A: T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia (2005) 19:652-658.
  • DOHNER H, STILGENBAUER S, BENNER A et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1910-1916.
  • GLASSMAN AB, HAYES KJ: The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet. Cytogenet. (2005) 158:88-91.
  • DAMLE RN, WASIL T, FAIS F et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94:1840-1847.
  • HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 94:1848-1854.
  • KROBER A, SEILER T, BENNER A et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 100:1410-1416.
  • ROSENBERG CL, WONG E, PETTY EM et al.: PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA (1991) 88:9638-9642.
  • RIMOKH R, BERGER F, DELSOL G et al.: Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood (1994) 83:1871-1875.
  • BERTONI F, ZUCCA E, COTTER FE: Molecular basis of mantle cell lymphoma. Br. J. Haematol. (2004) 124:130-140.
  • LI JY, GAILLARD F, MOREAU A et al.: Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am. J. Pathol. (1999) 154:1449-1452.
  • RAYNAUD SD, BEKRI S, LEROUX D et al.: Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer (1993) 8:80-87.
  • BOSCH F, JARES P, CAMPO E et al.: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood (1994) 84:2726-2732.
  • DE BOER CJ, VAN KRIEKEN JH, KLUIN-NELEMANS HC, KLUIN PM, SCHUURING E: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene (1995) 10:1833-1840.
  • AGUILERA NS, BIJWAARD KE, DUNCAN B et al.: Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am. J. Pathol. (1998) 153:1969-1976.
  • CAMPO E, RAFFELD M, JAFFE ES: Mantle-cell lymphoma. Semin. Hematol. (1999) 36:115-127.
  • JONES CD, DARNELL KH, WARNKE RA, ZEHNDER JL: Cyclin D1/Cyclin D3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma. J. Mol. Diagn. (2004) 6:84-89.
  • DE BOER CJ, VAN KRIEKEN JH, SCHUURING E, KLUIN PM: Bcl-1/cyclin D1 in malignant lymphoma. Ann. Oncol. (1997) 8:109-117.
  • ROSENWALD A, WRIGHT G, WIESTNER A et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 3:185-197.
  • DALLA-FAVERA R, BREGNI M, ERIKSON J, PATTERSON D, GALLO RC, CROCE CM: Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA (1982) 79:7824-7827.
  • HECHT JL, ASTER JC: Molecular biology of Burkitt's lymphoma. J. Clin. Oncol. (2000) 18:3707-3721.
  • NERI A, BARRIGA F, KNOWLES DM, MAGRATH IT, DALLA-FAVERA R: Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc. Natl. Acad. Sci. USA (1988) 85:2748-2752.
  • PELICCI PG, KNOWLES DM II, MAGRATH I, DALLA-FAVERA R: Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc. Natl. Acad. Sci. USA (1986) 83:2984-2988.
  • MACPHERSON N, LESACK D, KLASA R et al.: Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J. Clin. Oncol. (1999) 17:1558-1567.
  • HARALAMBIEVA E, SCHUURING E, ROSATI S et al.: Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. Genes Chromosomes Cancer (2004) 40:10-18.
  • JOOS S, FALK MH, LICHTER P et al.: Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. Hum. Mol. Genet. (1992) 1:625-632.
  • IIDA S, RAO PH, NALLASIVAM P et al.: The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood (1996) 88:4110-4117.
  • COOK JR, AGUILERA NI, RESHMI-SKARJA S et al.: Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum. Pathol. (2004) 35:447-454.
  • GEORGE TI, WREDE JE, BANGS CD, CHERRY AM, WARNKE RA, ARBER DA: Low grade B-cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements. J. Mol. Diag. (2005) 7:346-351.
  • SCHRIJVER I, ARBER DA: T-Cell Lymphomas. In: Molecular Pathology in Clinical Practice. Leonard DGB (Ed.), Springer, New York, USA (2007):365-371.
  • DE VILLARTAY J-P, HOCKETT RD, CORAN D, KORSMEYER SJ, COHEN DI: Deletion of the human T-cell receptor d-gene by a site-specific recombination. Nature (1988) 335:170-174.
  • DE VILLARTAY J-P, PULLMAN AB, ANDRADE R et al.: g/d lineage relationship within a consecutive series of human precursor T-cell neoplasms. Blood (1989) 74:2508-2518.
  • ZEMLIN M, HUMMEL M, ANAGNOSTOPOULOS I, STEIN H: Improved polymerase chain reaction detection of clonally rearranged T-cell receptor b chain genes. Diagn. Mol. Pathol. (1998) 7:138-145.
  • GREINER TC, RAFFELD M, LUTZ C, DICK F, JAFFE ES: Analysis of T cell receptor-g gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences. Am. J. Pathol. (1995) 146:46-55.
  • THEODOROU J, BIGORGNE C, DELFAU M-H et al.: VJ rearrangements of the TCRg locus in peripheral T-cell lymphomas: analysis by polymerase chain reaction and denaturing gradient gel electrophoresis. J. Pathol. (1996) 178:303-310.
  • GREINER TC, RUBOCKI RJ: Effectiveness of capillary electrophoresis using fluorescent-labeled primers in detecting T-cell receptor Γ gene rearrangements. J. Mol. Diagn. (2002) 4:137-143.
  • LE BEAU MM, BITTER MA, LARSON RA et al.: The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia (1989) 3:866-870.
  • MORRIS SW, KIRSTEIN MN, VALENTINE MB et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 263:1281-1284.
  • SARRIS AH, LUTHRA R, PAPADIMITRACOPOULOU V et al.: Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood (1996) 88:1771-1779.
  • KUTOK JL, ASTER JC: Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J. Clin. Oncol. (2002) 20:3691-3702.
  • ESCALON MP, LIU NS, YANG Y et al.: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer (2005) 103:2091-2098.
  • DREXLER HG, GIGNAC SM, VON WASIELEWSKI R, WERNER M, DIRKS WG: Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia (2000) 14:1533-1559.
  • BEYLOT-BARRY M, LAMANT L, VERGIER B et al.: Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am. J. Pathol. (1996) 149:483-492.
  • SCHUMACHER JA, JENSON SD, ELENITOBA-JOHNSON KS, LIM MS: Utility of linearly amplified RNA for RT-PCR detection of chromosomal translocations: validation using the t(2;5)(p23;q35) NPM-ALK chromosomal translocation. J. Mol. Diagn. (2004) 6:16-21.
  • PULFORD K, LAMANT L, MORRIS SW et al.: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood (1997) 89:1394-1404.
  • CATALDO KA, JALAL SM, LAW ME et al.: Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am. J. Surg. Pathol. (1999) 23:1386-1392.
  • LIANG X, MEECH SJ, ODOM LF et al.: Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am. J. Clin. Pathol. (2004) 121:496-506.
  • GASCOYNE RD, AOUN P, WU D et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 93:3913-3921.
  • FALINI B, PULFORD K, PUCCIARINI A et al.: Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood (1999) 94:3509-3515.
  • LI XQ, HISAOKA M, SHI DR, ZHU XZ, HASHIMOTO H: Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum. Pathol. (2004) 35:711-721.
  • WASIK MA: Expression of anaplastic lymphoma kinase in non-Hodgkin's lymphomas and other malignant neoplasms. Biological, diagnostic, and clinical implications. Am. J. Clin. Pathol. (2002) 118:S81-S92.
  • CHANG KL, WEISS LM: The association of the Epstein–Barr virus with malignant lymphoma. Biomed. Pharmacother. (1996) 50:459-467.
  • COHEN JI: Epstein–Barr virus infection. N. Engl. J. Med. (2000) 343:481-492.
  • YOUNG LS, RICKINSON AB: Epstein–Barr virus: 40 years on. Nat. Rev. Cancer (2004) 4:757-768.
  • STEVENS SJ, VERSCHUUREN EA, VERKUUJLEN SA, VAN DEN BRULE AJ, MEIJER CJ, MIDDELDORP JM: Role of Epstein–Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk. Lymphoma (2002) 43:831-840.
  • FISHER SG, FISHER RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene (2004) 23:6524-6534.
  • LAI R, WEISS LM: Hepatitis C virus and non-Hodgkin's lymphoma. Am. J. Clin. Pathol. (1998) 109:508-510.
  • PROVENCIO M, SANCHEZ A, BONILLA F, ESPANA P: HCV-associated lymphomas. Rev. Clin. Exp. Hematol. (2003) 7:406-423.
  • NEGRI E, LITTLE D, BOIOCCHI M, LA VECCHIA C, FRANCESCHI S: B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int. J. Cancer (2004) 111:1-8.
  • DUPIN N, FISHER C, KELLAM P et al.: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA (1999) 96:4546-4551.
  • HENGGE UR, RUZICKA T, TYRING SK et al.: Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1. Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect. Dis. (2002) 2:281-292.
  • HENGGE UR, RUZICKA T, TYRING SK et al.: Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2. Pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect. Dis. (2002) 2:344-352.
  • PAN L, MILLIGAN L, MICHAELI J, CESARMAN E, KNOWLES DM: Polymerase chain reaction detection of Kaposi's sarcoma-associated herpesvirus-optimized protocols and their application to myeloma. J. Mol. Diagn. (2001) 3:32-38.
  • HONG A, DAVIES S, LEE CS: Immunohistochemical detection of the human herpes virus 8 (HHV8) latent nuclear antigen-1 in Kaposi's sarcoma. Pathology (2003) 35:448-450.
  • GAAL K, SUN NC, HERNANDEZ AM, ARBER DA: Sinonasal NK/T-cell lymphomas in the United States. Am. J. Surg. Pathol. (2000) 24:1511-1517.
  • GAAL K, WEISS LM, CHEN WG, CHEN YY, ARBER DA: Epstein–Barr virus nuclear antigen (EBNA)-1 carboxy-terminal and EBNA-4 sequence polymorphisms in nasal natural killer/T-cell lymphoma in the United States. Lab. Invest. (2002) 82:957-962.
  • WHITE AC Jr, KATZ BZ, SILBERT JA: Association of Epstein–Barr virus with an angioimmunoblastic lymphadenopathy-like lymphoproliferative syndrome. Yale J. Biol. Med. (1989) 62:263-269.
  • LUZZATTO F, PRUNERI G, BENINI E et al.: Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. Histopathology (2005) 46:464-466.
  • MINAMOTO GY, GOLD JW, SCHEINBERG DA et al.: Infection with human T-cell leukemia virus type I in patients with leukemia. N. Engl. J. Med. (1988) 318:219-222.
  • NICOT C: Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am. J. Hematol. (2005) 78:232-239.
  • MULLER AM, IHORST G, MERTELSMANN R, ENGELHARDT M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann. Hematol. (2005) 84:1-12.
  • LEE TH, CHAFETS DM, BUSCH MP: Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR green chemistry. J. Clin. Virol. (2004) 31:275-282.
  • LAI R, ARBER DA, CHANG KL, WILSON CS, WEISS LM: Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod. Pathol. (1998) 11:864-869.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.